|
1
|
Le Grazie M, Biagini MR, Tarocchi M,
Polvani S and Galli A: Chemotherapy for hepatocellular carcinoma:
The present and the future. World J Hepatol. 9:907–920. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Goyal L, Zheng H, Abrams TA, Miksad R,
Bullock AJ, Allen JN, Yurgelun MB, Clark JW, Kambadakone A,
Muzikansky A, et al: A phase II and biomarker study of sorafenib
combined with modified FOLFOX in patients with advanced
hepatocellular carcinoma. Clin Cancer Res. 25:80–89. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yao S, Zhu Y and Chen L: Advances in
targeting cell surface signalling molecules for immune modulation.
Nat Rev Drug Discov. 12:130–146. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Feng F, Jiang Q, Jia H, Sun H, Chai Y, Li
X, Rong G, Zhang Y and Li Z: Which is the best combination of TACE
and Sorafenib for advanced hepatocellular carcinoma treatment? A
systematic review and network meta-analysis. Pharmacol Res.
135:89–101. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yuan T, Yan F, Ying M, Cao J, He Q, Zhu H
and Yang B: Inhibition of ubiquitin-specific proteases as a novel
anticancer therapeutic strategy. Front Pharmacol. 9:10802018.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sun CY, Li JY, Chu ZB, Zhang L, Chen L and
Hu Y: Efficacy and safety of bortezomib maintenance in patients
with newly diagnosed multiple myeloma: A meta-analysis. Biosci Rep.
37(pii): BSR201703042017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Robak T, Huang H, Jin J, Zhu J, Liu T,
Samoilova O, Pylypenko H, Verhoef G, Siritanaratkul N, Osmanov E,
et al: Bortezomib-based therapy for newly diagnosed mantle-cell
lymphoma. N Engl J Med. 372:944–953. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cui D, Xiong X and Zhao Y: Cullin-RING
ligases in regulation of autophagy. Cell Div. 11:82016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Maghames CM, Lobato-Gil S, Perrin A,
Trauchessec H, Rodriguez MS, Urbach S, Marin P and Xirodimas DP:
NEDDylation promotes nuclear protein aggregation and protects the
ubiquitin proteasome system upon proteotoxic stress. Nat Commun.
9:43762018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bhatia S, Pavlick AC, Boasberg P, Thompson
JA, Mulligan G, Pickard MD, Faessel H, Dezube BJ and Hamid O: A
phase I study of the investigational NEDD8-activating enzyme
inhibitor pevonedistat (TAK-924/MLN4924) in patients with
metastatic melanoma. Invest New Drugs. 34:439–449. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shah JJ, Jakubowiak AJ, O'Connor OA,
Orlowski RZ, Harvey RD, Smith MR, Lebovic D, Diefenbach C, Kelly K,
Hua Z, et al: Phase I study of the novel investigational
NEDD8-activating enzyme inhibitor pevonedistat (MLN4924in patients
with relapsed/refractory multiple myeloma or lymphoma. Clin Cancer
Res. 22:34–43. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sarantopoulos J, Shapiro GI, Cohen RB,
Clark JW, Kauh JS, Weiss GJ, Cleary JM, Mahalingam D, Pickard MD,
Faessel HM, et al: Phase I study of the investigational
NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in
patients with advanced solid tumors. Clin Cancer Res. 22:847–857.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Soucy TA, Smith PG, Milhollen MA, Berger
AJ, Gavin JM, Adhikari S, Brownell JE, Burke KE, Cardin DP,
Critchley S, et al: An inhibitor of NEDD8-activating enzyme as a
new approach to treat cancer. Nature. 458:732–736. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tong S, Si Y, Yu H, Zhang L, Xie P and
Jiang W: MLN4924 (Pevonedistat), a protein neddylation inhibitor,
suppresses proliferation and migration of human clear cell renal
cell carcinoma. Sci Rep. 7:55992017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Godbersen JC, Humphries LA, Danilova OV,
Kebbekus PE, Brown JR, Eastman A and Danilov AV: The
Nedd8-activating enzyme inhibitor MLN4924 thwarts
microenvironment-driven NF-κB activation and induces apoptosis in
chronic lymphocytic leukemia B cells. Clin Cancer Res.
20:1576–1589. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cheng M, Hu S, Wang Z, Pei Y, Fan R, Liu
X, Wang L, Zhou J, Zheng S, Zhang T, et al: Inhibition of
neddylation regulates dendritic cell functions via Deptor
accumulation driven mTOR inactivation. Oncotarget. 7:35643–35654.
2016.PubMed/NCBI
|
|
17
|
Lan H, Tang Z, Jin H and Sun Y:
Neddylation inhibitor MLN4924 suppresses growth and migration of
human gastric cancer cells. Sci Rep. 6:242182016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang Y, Luo Z, Pan Y, Wang W, Zhou X,
Jeong LS, Chu Y, Liu J and Jia L: Targeting protein neddylation
with an NEDD8-activating enzyme inhibitor MLN4924 induced apoptosis
or senescence in human lymphoma cells. Cancer Biol Ther.
16:420–429. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li H, Tan M, Jia L, Wei D, Zhao Y, Chen G,
Xu J, Zhao L, Thomas D, Beer DG and Sun Y: Inactivation of SAG/RBX2
E3 ubiquitin ligase suppresses KrasG12D-driven lung tumorigenesis.
J Clin Invest. 124:835–846. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Luo Z, Pan Y, Jeong LS, Liu J and Jia L:
Inactivation of the Cullin (CUL)-RING E3 ligase by the
NEDD8-activating enzyme inhibitor MLN4924 triggers protective
autophagy in cancer cells. Autophagy. 8:1677–1679. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mathewson N, Toubai T, Kapeles S, Sun Y,
Oravecz-Wilson K, Tamaki H, Wang Y, Hou G, Sun Y and Reddy P:
Neddylation plays an important role in the regulation of murine and
human dendritic cell function. Blood. 122:2062–2073. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lu C, Ning Z, Wang A, Chen D, Liu X, Xia
T, Tekcham DS, Wang W, Li T, Liu X, et al: USP10 suppresses tumor
progression by inhibiting mTOR activation in hepatocellular
carcinoma. Cancer Lett. 436:139–148. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Golob-Schwarzl N, Krassnig S, Toeglhofer
AM, Park YN, Gogg-Kamerer M, Vierlinger K, Schröder F, Rhee H,
Schicho R, Fickert P and Haybaeck J: New liver cancer biomarkers:
PI3K/AKT/mTOR pathway members and eukaryotic translation initiation
factors. Eur J Cancer. 83:56–70. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
He G and Karin M: NF-κB and STAT3-key
players in liver inflammation and cancer. Cell Res. 21:159–168.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Luo Z, Yu G, Lee HW, Li L, Wang L, Yang D,
Pan Y, Ding C, Qian J, Wu L, et al: The Nedd8-activating enzyme
inhibitor MLN4924 induces autophagy and apoptosis to suppress liver
cancer cell growth. Cancer Res. 72:3360–3371. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Crowley LC, Christensen ME and Waterhouse
NJ: Measuring survival of adherent cells with the colony-forming
assay. Cold Spring Harb Protoc 2016. 2016. View Article : Google Scholar
|
|
27
|
Xie CM, Chan WY, Yu S, Zhao J and Cheng
CHK: Bufalin induces autophagy-mediated cell death in human colon
cancer cells through reactive oxygen species generation and JNK
activation. Free Radic Biol Med. 51:1365–1375. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang J, Qiu Z and Wu Y: Ubiquitin
regulation: The histone modifying enzyme's story. Cells. 7(pii):
E1182018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gupta I, Singh K, Varshney NK and Khan S:
Delineating crosstalk mechanisms of the ubiquitin proteasome system
that regulate apoptosis. Front Cell Dev Biol. 6:112018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhou H, Xu J, Wang S and Peng J: Role of
cantharidin in the activation of IKKα/IκBα/NF-κB pathway by
inhibiting PP2A activity in cholangiocarcinoma cell lines. Mol Med
Rep. 17:7672–7682. 2018.PubMed/NCBI
|
|
31
|
Golabi P, Fazel S, Otgonsuren M, Sayiner
M, Locklear CT and Younossi ZM: Mortality assessment of patients
with hepatocellular carcinoma according to underlying disease and
treatment modalities. Medicine. 96:e59042017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wrzesinski SH, Taddei TH and Strazzabosco
M: Systemic therapy in hepatocellular carcinoma. Clin Liver Dis.
15:423–441, vii-x. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Medavaram S and Zhang Y: Emerging
therapies in advanced hepatocellular carcinoma. Exp Hematol Oncol.
7:172018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liu J, Liu Y, Meng L, Ji B and Yang D:
Synergistic antitumor effect of sorafenib in combination with ATM
inhibitor in hepatocellular carcinoma cells. Int J Med Sci.
14:523–529. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Shukla SK and Rafiq K: Proteasome biology
and therapeutics in cardiac diseases. Transl Res. 205:64–76. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Swords RT, Erba HP, DeAngelo DJ, Bixby DL,
Altman JK, Maris M, Hua Z, Blakemore SJ, Faessel H, Sedarati F, et
al: Pevonedistat (MLN4924), a First-in-Class NEDD8-activating
enzyme inhibitor, in patients with acute myeloid leukaemia and
myelodysplastic syndromes: A phase 1 study. Br J Haematol.
169:534–543. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lockhart AC, Bauer TM, Aggarwal C, Lee CB,
Harvey RD, Cohen RB, Sedarati F, Nip TK, Faessel H, Dash AB, et al:
Phase Ib study of pevonedistat, a NEDD8-activating enzyme
inhibitor, in combination with docetaxel, carboplatin and
paclitaxel, or gemcitabine, in patients with advanced solid tumors.
Invest New Drugs. 37:87–97. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lin S, Shang Z, Li S, Gao P, Zhang Y, Hou
S, Qin P, Dong Z, Hu T and Chen P: Neddylation inhibitor MLN4924
induces G2 cell cycle arrest, DNA damage and sensitizes
esophageal squamous cell carcinoma cells to cisplatin. Oncol Lett.
15:2583–2589. 2018.PubMed/NCBI
|
|
39
|
Swords RT, Coutre S, Maris MB, Zeidner JF,
Foran JM, Cruz J, Erba HP, Berdeja JG, Tam W, Vardhanabhuti S, et
al: Pevonedistat, a first-in-class NEDD8-activating enzyme
inhibitor, combined with azacitidine in patients with AML. Blood.
131:1415–1424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Paiva C, Godbersen JC, Berger A, Brown JR
and Danilov AV: Targeting neddylation induces DNA damage and
checkpoint activation and sensitizes chronic lymphocytic leukemia B
cells to alkylating agents. Cell Death Dis. 6:e18072015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wang X, Zhang W, Yan Z, Liang Y, Li L, Yu
X, Feng Y, Fu S, Zhang Y, Zhao H, et al: Radiosensitization by the
investigational NEDD8-activating enzyme inhibitor MLN4924
(pevonedistat) in hormone-resistant prostate cancer cells.
Oncotarget. 7:38380–38391. 2016.PubMed/NCBI
|
|
42
|
Oladghaffari M, Shabestani Monfared A,
Farajollahi A, Baradaran B, Mohammadi M, Shanehbandi D, Asghari
Jafar Abadi M and Pirayesh Islamian J: MLN4924 and 2DG combined
treatment enhances the efficiency of radiotherapy in breast cancer
cells. Int J Radiat Biol. 93:590–599. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wang S, Zhu M, Wang Q, Hou Y, Li L, Weng
H, Zhao Y, Chen D, Ding H, Guo J and Li M: Alpha-fetoprotein
inhibits autophagy to promote malignant behaviour in hepatocellular
carcinoma cells by activating PI3K/AKT/mTOR signalling. Cell Death
Dis. 9:10272018. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Liu X, Tian S, Liu M, Jian L and Zhao L:
Wogonin inhibits the proliferation and invasion, and induces the
apoptosis of HepG2 and Bel7402 HCC cells through NF-κB/Bcl-2, EGFR
and EGFR downstream ERK/AKT signaling. Int J Mol Med. 38:1250–1256.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Huang Y, Chen G, Wang Y, He R, Du J, Jiao
X and Tai Q: Inhibition of microRNA-16 facilitates the paclitaxel
resistance by targeting IKBKB via NF-κB signaling pathway in
hepatocellular carcinoma. Biochem Biophys Res Commun.
503:1035–1041. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wu S and Yu L: Targeting cullin-RING
ligases for cancer treatment: Rationales, advances and therapeutic
implications. Cytotechnology. 68:1–8. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Chen L, Liu T, Tu Y, Rong D and Cao Y:
Cul1 promotes melanoma cell proliferation by promoting DEPTOR
degradation and enhancing cap-dependent translation. Oncol Rep.
35:1049–1056. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Shi Z, Wu X, Ke Y and Wang L: Hint1
Up-Regulates IκBα by Targeting the β-TrCP subunit of SCF E3 ligase
in human hepatocellular carcinoma cells. Dig Dis Sci. 61:785–794.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Jin J, Shen X, Chen L, Bao LW and Zhu LM:
TMPRSS4 promotes invasiveness of human gastric cancer cells through
activation of NF-κB/MMP-9 signaling. Biomed Pharmacother. 77:30–36.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Lu P, Chen J, Yan L, Yang L, Zhang L, Dai
J, Hao Z, Bai T, Xi Y, Li Y, et al: RasGRF2 promotes migration and
invasion of colorectal cancer cells by modulating expression of
MMP9 through Src/Akt/NF-κB pathway. Cancer Biol Ther. 20:435–443.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Kang MH, Oh SC, Lee HJ, Kang HN, Kim JL,
Kim JS and Yoo YA: Metastatic function of BMP-2 in gastric cancer
cells: The role of PI3K/AKT, MAPK, the NF-κB pathway, and MMP-9
expression. Exp Cell Res. 317:1746–1762. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Xu CY, Qin MB, Tan LIN, Liu SQ and Huang
JA: NIBP impacts on the expression of E-cadherin, CD44 and vimentin
in colon cancer via the NF-κB pathway. Mol Med Rep. 13:5379–5385.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Li H, Zhou W, Li L, Wu J, Liu X, Zhao L,
Jia L and Sun Y: Inhibition of neddylation modification sensitizes
pancreatic cancer cells to gemcitabine. Neoplasia. 19:509–518.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Zheng W, Luo Z, Zhang J, Min P, Li W, Xu
D, Zhang Z, Xiong P, Liang H and Liu J: Neural precursor cell
expressed, developmentally downregulated 8-activating enzyme
inhibitor MLN4924 sensitizes colorectal cancer cells to oxaliplatin
by inducing DNA damage, G2 cell cycle arrest and apoptosis. Mol Med
Rep. 15:2795–2801. 2017. View Article : Google Scholar : PubMed/NCBI
|
